I started working at MediChem Life Sciences, a drug discovery and technology company, in a finance role when I graduated from college. deCODE Genetics acquired MediChem three years later, and I stayed on as vice president of finance at the Icelandic company’s U.S. office. Later, I became chief financial officer of Emerald Bio when the company spun out from deCODE in 2009…Read More
Our mission is to provide best-in-class lead discovery solutions. Our proven teams of drug discovery professionals are passionate about unlocking the therapeutic potential of both genetically- and clinically-validated drug targets, and in developing new therapeutic modalities. We work in partnership with our clients to address the most difficult scientific and business challenges facing drug discovery, and to ultimately enable transformational health care outcomes.
A MARKET IN FLUX.
All levels of the research-based pharmaceutical industry is in the midst of significant change as economic, regulatory and scientific challenges dictate the efficiencies of drug discovery. Large pharmaceutical companies are seeking ways to enhance the quantity and quality of their pipelines with less risk. Smaller companies are developing lean/virtual models that are based on focused, therapeutic development, while academic and institutional research organizations are mitigating a decrease in government funding by attempting to develop commercial partnerships to offset the drop in traditional funding.
AN OPPORTUNITY TO MAKE A DIFFERENCE.
The progression from invention to innovation (i.e. discovery) is being affected by these changes. Beryllium is uniquely positioned to serve the needs of this evolving landscape. Moreover, we have a successful track record in pursuing targets that have not been drugged before, opening the door to both genetically- and clinically-validated targets, and developing new therapeutic modalities. We are enabling novel drug discovery by marrying world-class structural and functional biology-centric platforms with drug discovery process expertise. Our goal is to deliver validated starting points that improve the success of drug development programs and most importantly- make a difference to patients.
With over a decade of industry expertise, I have been at the forefront of numerous, successful structure determination research collaborations, including hepatitis C virus (HCV), oncology and diabetes targets. Prior to joining Beryllium, I was a crystallographer and senior research scientist at the Seattle Structural Genomics Center for Infectious Disease (SSGCID)…Read More
I began my career in the biotech industry in 1995 and it has included positions at Thermo Fisher and Lonza Biologics. I earned my Bachelor’s degree from Old Dominion University. As a Navy spouse I had the opportunity to live all over the world from Italy to Hawaii to Washington State…Read More
Doug Davies, Ph.D.
I have been working with an interdisciplinary team to build and strengthen fragment-based discovery at Beryllium for ten years. I worked as the project lead on the effort to build our first in-house fragment screening collection, the metabolome-influenced “Fragments of Life.” …Read More